MeiraGTx Holdings plc Lease, Cost
MeiraGTx Holdings plc (MGTX) reported Lease, Cost of $1.51 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:LeaseCost · last filed 2026-08-13
- MeiraGTx Holdings plc lease, cost for the quarter ending 2026-06-30 was $1.51M, a 0.20% decline year-over-year.
- MeiraGTx Holdings plc lease, cost for the quarter ending 2026-03-31 was $1.61M, a 6.26% increase year-over-year.
- MeiraGTx Holdings plc lease, cost for the quarter ending 2025-12-31 was $1.72M, a 5.90% increase year-over-year.
- MeiraGTx Holdings plc lease, cost for the quarter ending 2025-09-30 was $1.68M, a 2.15% decline year-over-year.
- MeiraGTx Holdings plc lease, cost for fiscal 2025 was $6.58M, a 4.11% decline from fiscal 2024.
- MeiraGTx Holdings plc lease, cost for fiscal 2024 was $6.87M, a 1.64% increase from fiscal 2023.
- MeiraGTx Holdings plc lease, cost for fiscal 2023 was $6.76M, a 2.91% increase from fiscal 2022.
- MeiraGTx Holdings plc lease, cost for fiscal 2022 was $6.57M, a 5.97% decline from fiscal 2021.
| Period end | Lease, Cost 3 month | Lease, Cost 3 month as first filed | Lease, Cost 6 month | Lease, Cost 6 month as first filed | Lease, Cost 9 month | Lease, Cost 9 month as first filed | Lease, Cost 12 month | Lease, Cost 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $1.51M 10-Q · filed 2026-08-13 | $3.13M 10-Q · filed 2026-08-13 | $4.85M derived: sum of 3 quarters · filed 2026-08-13 | $6.53M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2026-03-31 | $1.61M 10-Q · filed 2026-05-14 | $3.33M derived: sum of 2 quarters · filed 2026-05-14 | $5.02M derived: sum of 3 quarters · filed 2026-05-14 | $6.54M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-12-31 | $1.72M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $3.41M derived: sum of 2 quarters · filed 2026-03-30 | $4.92M derived: sum of 3 quarters · filed 2026-08-13 | $6.58M 10-K · filed 2026-03-30 | ||||
| 2025-09-30 | $1.68M 10-Q · filed 2025-11-13 | $3.20M derived: sum of 2 quarters · filed 2026-08-13 | $4.86M 10-Q · filed 2025-11-13 | $6.34M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-06-30 | $1.52M 10-Q · filed 2026-08-13 | $3.18M 10-Q · filed 2026-08-13 | $4.66M derived: sum of 3 quarters · filed 2026-08-13 | $6.38M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-03-31 | $1.52M 10-Q · filed 2026-05-14 | $3.14M derived: sum of 2 quarters · filed 2026-05-14 | $4.86M derived: sum of 3 quarters · filed 2026-05-14 | $6.62M derived: sum of 4 quarters · filed 2026-05-14 | ||||
| 2024-12-31 | $1.63M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $3.35M derived: sum of 2 quarters · filed 2026-03-30 | $5.11M derived: sum of 3 quarters · filed 2026-03-30 | $6.87M 10-K · filed 2026-03-30 | ||||
| 2024-09-30 | $1.72M 10-Q · filed 2025-11-13 | $3.48M derived: sum of 2 quarters · filed 2025-11-13 | $5.24M 10-Q · filed 2025-11-13 | $6.93M derived: sum of 4 quarters · filed 2025-11-13 | ||||
| 2024-06-30 | $1.76M 10-Q · filed 2025-08-14 | $3.52M 10-Q · filed 2025-08-14 | $5.21M derived: sum of 3 quarters · filed 2025-08-14 | $6.90M derived: sum of 4 quarters · filed 2025-08-14 | ||||
| 2024-03-31 | $1.76M 10-Q · filed 2025-05-13 | $3.46M derived: sum of 2 quarters · filed 2025-05-13 | $5.14M derived: sum of 3 quarters · filed 2025-05-13 | $6.83M derived: sum of 4 quarters · filed 2025-05-13 | ||||
| 2023-12-31 | $1.70M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $3.38M derived: sum of 2 quarters · filed 2025-03-13 | $5.07M derived: sum of 3 quarters · filed 2025-03-13 | $6.76M 10-K · filed 2025-03-13 | ||||
| 2023-09-30 | $1.69M 10-Q · filed 2024-11-13 | $3.38M derived: sum of 2 quarters · filed 2024-11-13 | $5.06M 10-Q · filed 2024-11-13 | $6.70M derived: sum of 4 quarters · filed 2024-11-13 | ||||
| 2023-06-30 | $1.69M 10-Q · filed 2024-08-12 | $3.37M 10-Q · filed 2024-08-12 | $5.01M derived: sum of 3 quarters · filed 2024-08-12 | $6.62M derived: sum of 4 quarters · filed 2024-08-12 | ||||
| 2023-03-31 | $1.68M 10-Q · filed 2024-05-09 | $3.32M derived: sum of 2 quarters · filed 2024-05-09 | $4.93M derived: sum of 3 quarters · filed 2024-05-09 | $6.58M derived: sum of 4 quarters · filed 2024-05-09 | ||||
| 2022-12-31 | $1.64M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-15 | $3.25M derived: sum of 2 quarters · filed 2024-03-15 | $4.90M derived: sum of 3 quarters · filed 2024-03-15 | $6.57M 10-K · filed 2024-03-15 | ||||
| 2022-09-30 | $1.61M 10-Q · filed 2023-11-14 | $3.26M derived: sum of 2 quarters · filed 2023-11-14 | $4.93M 10-Q · filed 2023-11-14 | $6.61M derived: sum of 4 quarters · filed 2023-11-14 | ||||
| 2022-06-30 | $1.65M 10-Q · filed 2023-08-10 | $3.32M 10-Q · filed 2023-08-10 | $5.00M derived: sum of 3 quarters · filed 2023-08-10 | $6.78M derived: sum of 4 quarters · filed 2023-08-10 | ||||
| 2022-03-31 | $1.65M 10-Q · filed 2023-05-11 | $3.35M derived: sum of 2 quarters · filed 2023-05-11 | $5.13M derived: sum of 3 quarters · filed 2023-05-11 | $6.97M derived: sum of 4 quarters · filed 2023-05-11 | ||||
| 2021-12-31 | $1.70M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-14 | $3.48M derived: sum of 2 quarters · filed 2023-03-14 | $5.32M derived: sum of 3 quarters · filed 2023-03-14 | $6.98M 10-K · filed 2023-03-14 | ||||
| 2021-09-30 | $1.78M 10-Q · filed 2022-11-10 | $3.62M derived: sum of 2 quarters · filed 2022-11-10 | $5.28M 10-Q · filed 2022-11-10 | $6.59M derived: sum of 4 quarters · filed 2022-11-10 | ||||
| 2021-06-30 | $1.84M 10-Q · filed 2022-08-11 | $3.48M 10-Q · filed 2022-08-11 | $4.81M derived: sum of 3 quarters · filed 2022-08-11 | $5.91M derived: sum of 4 quarters · filed 2022-08-11 | ||||
| 2021-03-31 | $1.64M 10-Q · filed 2022-05-12 | $2.97M derived: sum of 2 quarters · filed 2022-05-12 | $4.07M derived: sum of 3 quarters · filed 2022-05-12 | $5.22M derived: sum of 4 quarters · filed 2022-05-12 | ||||
| 2020-12-31 | $1.33M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | $2.43M derived: sum of 2 quarters · filed 2022-03-10 | $3.58M derived: sum of 3 quarters · filed 2022-03-10 | $4.66M 10-K · filed 2022-03-10 | $4.66M 10-K · filed 2021-03-11 | |||
| 2020-09-30 | $1.10M 10-Q · filed 2021-11-10 | $1.10M 10-Q · filed 2020-11-05 | $2.25M derived: sum of 2 quarters · filed 2021-11-10 | $3.33M 10-Q · filed 2021-11-10 | $3.33M 10-Q · filed 2020-11-05 | $5.04M derived: sum of 4 quarters · filed 2021-11-10 | ||
| 2020-06-30 | $1.15M 10-Q · filed 2021-08-11 | $1.15M 10-Q · filed 2020-08-06 | $2.23M 10-Q · filed 2021-08-11 | $2.23M 10-Q · filed 2020-08-06 | $3.94M derived: sum of 3 quarters · filed 2021-08-11 | $5.14M derived: sum of 4 quarters · filed 2021-08-11 | ||
| 2020-03-31 | $1.26M 10-Q · filed 2021-05-11 | $1.26M 10-Q · filed 2020-05-07 | $2.78M derived: sum of 2 quarters · filed 2021-05-11 | $3.99M derived: sum of 3 quarters · filed 2021-05-11 | $4.70M derived: sum of 4 quarters · filed 2021-05-11 | |||
| 2019-12-31 | $1.52M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-11 | $2.73M derived: sum of 2 quarters · filed 2021-03-11 | $3.43M derived: sum of 3 quarters · filed 2021-03-11 | $3.97M 10-K · filed 2021-03-11 | ||||
| 2019-09-30 | $1.21M 10-Q · filed 2020-11-05 | $1.91M derived: sum of 2 quarters · filed 2020-11-05 | $2.45M 10-Q · filed 2020-11-05 | |||||
| 2019-06-30 | $705.37K 10-Q · filed 2020-08-06 | $204.78K 10-Q · filed 2019-08-07 | $1.20M 10-Q · filed 2020-08-06 | $425.86K 10-Q · filed 2019-08-07 | ||||
| 2019-03-31 | $221.08K 10-Q · filed 2020-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |